Objective: The safety of stenting for intracranial internal carotid artery stenosis using flow reversal embolic protection was evaluated.
Introduction
The recurrence rate of symptomatic intracranial internal carotid artery stenosis is known to be high with antithrombotic therapy alone, 1, 2, 3) and intracranial stenting was expected to be effective for its treatment, but its effectiveness was rejected by a randomized clinical trial. 4) Presently, stenting for intracranial arterial stenosis is regarded as a treatment worth considering only when symptoms appear despite internal treatment and exert serious effects on hemodynamics according to the Japanese guideline for the management of stroke 2015. 5) In stenting for intracranial internal carotid artery stenosis, avoidance of hemorrhagic or embolic complications is important to obtain a favorable outcome. In this study, we evaluated stenting with flow reversal, which we perform as a treatment for intracranial internal carotid artery stenosis.
Subjects and Methods
The subjects were 13 patients with 70% or severer stenosis of the intracranial internal carotid artery who underwent endovascular treatment (angioplasty and stenting) between April 2011 and September 2016. The 13 patients were divided into four early cases treated with no flow reversal (with no protection or with proximal protection: group N) and nine late cases treated with flow reversal (group F), and the postprocedural technical success rate, stroke rate, and diffusion-weighted imaging (DWI)-positive rate were compared. The preprocedural condition of the site of stenosis was evaluated by DSA, and dualantiplatelet therapy (aspirin at 100 mg/day, clopidogrel at 75 mg/day) was performed for at least 1 week before the procedure. In both groups, after placing a 5 Fr. sheath in the femoral artery under local or general anesthesia, DSA was performed using a 5 Fr. diagnostic catheter, and the site of stenosis, stenosis rate, and lesion length were measured. After replacing the sheath with a 6 Fr. or 9 Fr. device, systemic heparinization was performed, and the intraprocedural activated clotting time (ACT) was maintained at 250 seconds or longer.
In the group N, 6 Fr. Chaperon (Terumo Corporation, Tokyo, Japan) or 9 Fr. OPTIMO (Tokai Medical Products, Aichi, Japan) was placed in the internal carotid artery as a guiding catheter. Lesion cross was made using a microguidewire, the lesion was dilated using Gateway (Stryker, Fremont, CA, USA), and Integrity (Medtronic, Minneapolis, MN, USA) or Driver (Medtronic), which are coronary stent systems, was placed. Predilatation and stenting were performed without protection if 6 Fr. Chaperon was used as the guiding catheter and with occlusion by inflating the balloon if 9 Fr. OPTIMO was used. Then, 50-100 mL of blood was manually aspirated, and, after confirming the absence of floating thrombi, occlusion was released.
In the group F, a 5 Fr. sheath was also placed in the femoral vein, 9 Fr. OPTIMO was placed in the internal carotid artery as a guiding catheter, connected with the sheath in the femoral vein via a Y connector of the 9 Fr. OPTIMO by interposing a transfusion filter before balloon occlusion, and a complete flow reversal condition was prepared. Lesion cross was made using a microguidewire, the site of stenosis was predilated using Gateway (Stryker), and Integrity or Wingspan stent (Stryker) was placed at the site of stenosis.
In both groups, MRI was performed on the day after the procedure, and the presence or absence of new foci of cerebral infarction was checked by DWI. As a follow-up, the stenting site was examined by 3D-CTA or DSA in addition to neurologic evaluation after 3 months. Table 1 shows the details of each group. The mean age was 63.3 and 69.6 years in the groups N and F, respectively. The onset pattern was minor stroke (MnS) in three patients (75%) in the group N and two patients (22%) in the group F but one patient (25%) in group N and four patients (45%) in group F were asymptomatic; the frequency of MnS was high in the group N. The site of stenosis was the petrous portion in 78% in the group F. Anesthesia was local in all patients in the group N but general in all but the first patient in the group F in consideration of the possibility of occlusion intolerance. The length of stenosis was 5-10 mm in all patients (Mori Type B) with no difference between the two groups. Table 2 shows the devices used and complications in individual patients. Two representative cases, i.e., Case 4 that suffered an embolic complication and Case 10 that underwent stenting with flow reversal, are presented.
Results
Case 4 was a 59-year-old male ( Fig. 1) who had undergone carotid artery stenting (CAS) for right cervical carotid artery stenosis at another hospital. He consulted a local doctor due to amaurosis fugax and was found to have stenosis of the left intracranial internal carotid artery. DSA confirmed 85% stenosis in the petrous segment of the left internal carotid artery (Fig. 1a) , and stenting was performed. The internal carotid artery was occluded with 9 Fr. OPTIMO, and after predilatation using Gateway, Integrity was placed. Occlusion was released after manually aspirating about 100 mL of blood, and angiography showed improvement of the stenosis rate to nearly 0% (Fig. 1b  and 1c) . However, dysarthria and right hemiparesis appeared immediately after the release of occlusion. MRI immediately after the procedure showed new diffuse hyperintensities in the left middle cerebral artery territory (Fig. 1d) . With dysarthria and right hemiparesis persisting, the patient was transferred to a rehabilitation hospital on the 10th postprocedural day with a modified Rankin scale (mRS) score of 2.
Case 10 was a 65-year-old male (Fig. 2) who consulted the outpatient clinic due to dizziness and dysarthria. MRI showed a focus of subacute infarction in the left parietal lobe (Fig. 2a) , and DSA showed 90% stenosis of the petrous segment of the left internal carotid artery (Fig. 2b) .
After 3 weeks, stenting was performed with flow reversal. In a flow-reversed state, Integrity was placed after predilatation using Gateway. Since plaque shift was noted after stent placement (Fig. 2c) , blood flow was reversed again, and an additional Wingspan stent was placed, resulting in an improvement of the stenosis rate to nearly 0% ( Fig. 2d and 2e) . There was no change in neurologic symptoms after the procedure, no new foci of cerebral infarction were noted on MRI after 3 days (Fig. 2f) , and the patient was discharged to home 7 days after admission.
The technical success rate was 100% in both groups, but the stroke rate was 25%, and the DWI-positive rate was 25%, in the group N. In the group F, no complication was noted, and the stroke rate and DWI-positive rate were both 0% ( Table 3) .
Discussion
The recurrence rate of intracranial internal artery stenosis is known to be high after medical treatment with antiplatelet agents. 1,2,3) Angioplasty using a balloon catheter for intracranial arterial stenosis began in the 1990s. Mori et al. classified lesions into three types (type A, short concentric; type B, tubular extremely eccentric; and type C, diffuse) and reported the long-term prognosis after balloon angioplasty. In type A, effective dilatation could be obtained with low risk, and a relatively favorable long-term outcome could be expected. In types B and C, however, the risk was high, and effective dilatation could not be achieved in many patients. 6) To overcome such problems with the balloon catheter, metal stents were introduced with a high expectation, and their effectiveness and favorable therapeutic results have been reported. 7, 8) We used coronary stenosis in majority of cases. In the patients reported here, the DWI-positive rate after stenting with flow reversal was 0%, indicating a high preventive effect against distal embolism.
Conclusion
Stenting with flow reversal is likely to be an effective and safe treatment for intracranial internal carotid artery stenosis.
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artery stents in 11 of our 13 patients, but the application of balloon expandable stents for the coronary artery to intracranial vessels is limited to particular sites such as non-curved and lesions with low volume plaque. Under such circumstances, great expectations were directed to the Wingspan, which is a self-expandable stent, but many periprocedural ischemic complications were reported in a randomized clinical trial, and the outcomes were clearly inferior to those of medical treatment. 4) The poor outcome may be explained by occlusion of perforating arteries and distal embolism. In stenting for the intracranial internal carotid artery stenosis, in which the amount of plaque is smaller than in stenosis of the origin of the carotid artery, occlusion of perforating arteries tends to be regarded as a greater concern than distal embolism. Indeed, three-fourths of the lesions had many perforating arteries in the SAMMPRIS study, and their occlusion may have contributed to the increase in ischemic complications. Regarding distal embolic protection in stenting for intracranial internal carotid artery stenosis, there is a report that complications due to distal embolism were rare even without special protection such as proximal flow control, 9) on the contrary, there is a report recommending aggressive proximal protection. 10) In our Case 4, obvious shower emboli were caused despite implementation of proximal protection, and proximal protection alone was suggested to be insufficient to prevent distal embolism due to plaque rupture. After experiencing this case, we performed stenting with flow reversal.
In cervical CAS, devices for the prevention of distal embolism have been developed with time. Satoh et al. reported that the DWI-positive rate after CAS was 64% when the filter type ANGIOGUARD XP (Cordis, Milpitas, CA, USA) was used but was reduced to 17.8% by combining distal occlusion using PercuSurge GuardWire (Medtronic) with blood aspiration. 11) In addition, the effectiveness of the Parodi antiembolic system in CAS has been demonstrated, and there is a report that the incidence of stroke or death within 30 days after treatment could be reduced to 1.5% by this method. 12) Also, Asakura et al. reported that the DWI-positive rate after CAS using the Parodi antiembolic system was 18.2% and did not differ significantly compared with 11.5% using diagnostic angiography. 13) In CAS, complete flow reversal may not be implemented with the Parodi antiembolic system due to the presence of the superior thyroid artery. However, complete flow reversal can be achieved in intracranial internal carotid artery
